Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Palmoplantar Keratoderma Market Size Forecast: How Big Could The Market Get By 2030?
The palmoplantar keratoderma market size has experienced consistent expansion in recent years. Projections indicate it will increase from $0.88 billion in 2025 to $0.92 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.9%. The growth observed in prior periods can be attributed to an uptick in the diagnosis of rare dermatological disorders, the expansion of dermatology specialty clinics, the wider application of retinoid therapies, greater patient awareness regarding genetic skin diseases, and advancements in dermatopathology testing.
The palmoplantar keratoderma market size is predicted to undergo substantial expansion in the coming years. By 2030, it is projected to attain a valuation of $1.13 billion, expanding at a compound annual growth rate (CAGR) of 5.2%. This market expansion throughout the forecast period stems from advancements in targeted dermatology drugs, wider availability of genetic screening, increasing adoption of biologic therapy, a surge in specialty dermatology pipelines, and enhanced support programs for orphan diseases. Significant trends anticipated for the forecast period comprise specialized biologic skin therapies, sophisticated genetic diagnostic panels, extended-release topical formulations, dual retinoid treatment protocols, and the integration of home-based phototherapy.
Get A Free Sample Report With In-Depth Market Insights:
Palmoplantar Keratoderma Market Growth Momentum: What Factors Are Shaping Demand?
The growing occurrence of genetic mutations is anticipated to stimulate the expansion of the palmoplantar keratoderma market in the coming years. Genetic mutations refer to alterations or divergences in DNA sequences that can heighten vulnerability to inherited conditions and skin ailments. The frequency of genetic mutations is increasing due to progress in genomic sequencing and extensive genetic testing, facilitating the discovery and identification of more previously unknown DNA variations throughout populations. An increase in genetic mutations contributes to palmoplantar keratoderma by expanding the segment of the population with inherited skin-gene modifications, consequently leading to prompt identification and an elevated requirement for specific treatments. For instance, in January 2023, data from a report by the National Center for Biotechnology Information (NCBI), a part of the US-based National Library of Medicine (NLM), revealed that with roughly 140 million babies born annually, approximately 9.8 billion new human mutations are introduced into the gene pool each year. Consequently, the rising prevalence of genetic mutations is a key factor driving the growth of the palmoplantar keratoderma market. Growing financial outlays on healthcare are anticipated to propel the expansion of the palmoplantar keratoderma market moving forward. Healthcare expenditure denotes the aggregate sum of monetary resources allocated for health services, encompassing medical treatments, diagnostic procedures, medications, and preventative care. This spending is on the rise primarily due to an aging global population, as older individuals exhibit higher incidences of chronic illnesses, necessitate more frequent medical interventions, and often require extended periods of treatment, thereby pushing overall healthcare costs upward. Enhanced healthcare spending benefits palmoplantar keratoderma by improving patient access to specialized medical attention, providing funds for advanced diagnostic tools and therapies, and facilitating timely, individualized treatment approaches. For example, in January 2026, the Centers for Medicare & Medicaid Services, a US-based government body, reported that in 2024, national health expenditure (NHE) saw a 7.2% increase, reaching $5.3 trillion, which translates to an average of $15,474 per person and constituted 18.0% of GDP, while Medicare spending grew by 7.8% to $1,118.0 billion, making up 21% of total NHE. Consequently, the surge in healthcare expenditure is a significant factor driving the growth of the palmoplantar keratoderma market.
Palmoplantar Keratoderma Market Segment Analysis: What Are The Core Market Categories?
The palmoplantar keratoderma market covered in this report is segmented –
1) By Treatment Type: Topical Treatments; Systemic Treatments; Phototherapy; Surgical Interventions
2) By Type: Non Lamellar Keratoderma; Lamellar Keratoderma; Epidermolytic Keratoderma; Palmoplantar Keratoderma With Systemic Involvement
3) By Diagnosis Method: Clinical Examination; Histopathological Examination; Genetic Testing
4) By Patient Type: Pediatric; Adult
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Topical Treatments: Salicylic Acid Preparations; Urea Creams; Emollients; Retinoid Creams; Corticosteroid Creams
2) By Systemic Treatments: Oral Retinoids; Oral Vitamin D Analogues; Oral Corticosteroids; Oral Immunosuppressants
3) By Phototherapy: Ultraviolet A Therapy; Ultraviolet B Therapy; Psoralen Plus Ultraviolet A Therapy
4) By Surgical Interventions: Excision Surgery; Laser Therapy; Dermabrasion; Skin Grafting
Palmoplantar Keratoderma Market Trends Redefining Industry Growth
Leading companies within the palmoplantar keratoderma market are prioritizing clinical trials to develop innovative drugs, such as TRPV3 inhibitors, aiming to provide targeted, disease-modifying treatments that offer more than just symptomatic relief. These TRPV3 inhibitors work by blocking the TRPV3 ion channel, which helps to normalize skin cell growth, strengthen the skin barrier, and reduce the pain and thickening associated with palmoplantar keratoderma. For instance, in June 2024, Kamari Pharma Ltd., a clinical-stage biotechnology company, launched KM-001, a topical TRPV3 inhibitor, following encouraging Phase 1b clinical results. KM-001 is formulated as a cream applied twice daily and has demonstrated high safety with no severe adverse events, along with an overall responder rate of 87% in patients with pachyonychia congenita and punctate palmoplantar keratoderma type 1. Its unique mechanism aids in normalizing skin cell proliferation, enhancing epidermal barrier formation, and reducing pain in affected patients, offering a disease-modifying alternative to conventional treatments. Kamari Pharma intends to advance KM-001 into Phase 2 trials while simultaneously developing KM-023, an oral TRPV3 inhibitor, for broader keratoderma indications.
Palmoplantar Keratoderma Market Key Players Shaping Industry Direction
Major companies operating in the palmoplantar keratoderma market are LEO Pharma, Krystal Biotech Inc., and Kamari Pharma.
View The Full Palmoplantar Keratoderma Market Report:
Palmoplantar Keratoderma Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the palmoplantar keratoderma market in 2025. Asia – Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the palmoplantar keratoderma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
